HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Board Seat Swings To Peltz In Ongoing Vote Tally

This article was originally published in The Pink Sheet

Executive Summary

P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.

You may also be interested in...



P&G Counts Board Vote Win As Peltz Claims 'Change' Message Delivered

Procter & Gamble says preliminary results keep billionaire activist investor Nelson Peltz off its board and re-elect its 11 incumbents. However, Peltz plans to challenge the vote outcome and analysts agree that his pressure for change at P&G scored points with shareholders.

As P&G Board Vote Looms, Activist Investor Peltz Gains Endorsements

As Procter & Gamble prepares for a shareholder vote that could shake up its board and its strategies, proxy advisor Glass, Lewis & Co. recommends shareholders vote in favor of electing Trian Fund Management CEO Nelson Peltz, who's pressing the firm for dramatic operational changes.

P&G Open To M&A Moves, Closed To Board Seat For Activist Investor

P&G posts 2% organic growth in its latest quarter and its adjusted EPS beat analyst expectations as it is again interested in M&A. A few days after releasing its results, company appeals to shareholders to vote against an activist investor's bid for a board seat.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel